Latest News
Dec 5, 2018
ReViral Board member Raymond Schinazi decorated with French Legion of Honour

Atlanta, USA, 4th December 2018 / The Consulate General of France in Atlanta honored Raymond Schinazi, PhD, DSc, for his receipt of the Chevalier de la Légion d’honneur - the French...

Dec 4, 2018
Virologist position

ReViral are currently recruiting a Virologist to join our laboratory team based in Stevenage, UK.

This is a practical laboratory-based position and we are looking for an experienced graduate level...

Nov 14, 2018
ReViral Announces Publication of Article in Journal of Medicinal Chemistry 'Perspectives'

ReViral today announced that the article “State of the Art in Respiratory Syncytial Virus Drug Discovery and Development”, written by ReViral’s Dr Stuart Cockerill, Dr James Good and Dr Neil...

Oct 8, 2018
ReViral at 11th International Respiratory Syncytial Virus Symposium

ReViral's CEO, Dr Eddy Littler, and Head of Virology, Dr Elaine Thomas, will be presenting "Low rate of resistance to the RSV fusion inhibitor RV521 in human infection" at the 11th International Respiratory...

Oct 8, 2018
ReViral to present at RespiDART 2018

ReViral's Chief Scientific Officer, Stuart Cockerill, will be presenting at RespiDART 2018 in Miami on 29th November 2018. The afternoon session entitled "Therapeutics against respiratory viruses: Clinical advances...

Oct 8, 2018
ReViral at 6th ISIRV AVG Conference

ReViral's Chief Operating Officer, Dr Rachel Harland, will be presenting the poster "Efficacy of the RSV fusion Inhibitor RV521 in human infection" at The 6th ISIRV AVG Conference in Washington DC, USA (13th - 15th...

Aug 1, 2018
ReViral announces Series B investment

ReViral announces US$55 million series B fundraising to advance RSV clinical studies

London, UK – 1st August 2018:  ReViral, an antiviral drug discovery and development company,...

Feb 5, 2018
Positive results achieved in ReViral’s Phase IIa RSV challenge study

ReViral’s RV521 fusion inhibitor produces highly significant reduction in viral load and clinical symptoms

London, UK, 5th February 2018 / ReViral, a UK-based biotech...

Archived News
Sep 5, 2017
ReViral initiates Phase 2a study of RV521 for treatment of Respiratory Syncytial Virus
Apr 24, 2017
ReViral Announces Good Safety and Pharmacokinetics From Phase 1 Programme for RSV Antiviral RV521 in Healthy Volunteers
Sep 8, 2015
ReViral announces US$21 million fundraising to advance clinical development of a novel anti-viral drug
Upcoming Events
J.P. Morgan 37th Annual Healthcare Conference
Jan 7, 2019 to Jan 10, 2019
San Francisco
More Information
Past Events
11th International Respiratory Syncytial Virus Symposium
Oct 31, 2018 to Nov 4, 2018
Asheville, NC, USA
More Information
24th Annual BioEurope Partnering Conference
Nov 5, 2018 to Nov 7, 2018
Copenhagen
More Information
The 6th ISIRV AVG Conference
Nov 13, 2018 to Nov 15, 2018
Washington
More Information
RespiDART 2018
Nov 29, 2018 to Nov 30, 2018
Miami
More Information
Genesis 2018
Dec 13, 2018